Research across Blood Coagulation Disorders, Inherited
Related studies from across the Blood Coagulation Disorders, Inherited family.
Gene therapy reduces bleeding rates and factor use in adults with severe hemophilia A
Can gene therapy reduce bleeding and treatment burden for adults with severe hemophilia A?
A systematic review and meta-analysis of adults with severe/moderately severe hemophilia A found gene therapy reduced annualized bleeding ra…
For adults with severe hemophilia A, gene therapy may offer a way to bleed less and rely far less on regular infusions.
Phase 3 trial of damoctocog alfa pegol in previously treated children with severe haemophilia A
Phase 3 trial studies new treatment for severe haemophilia A in children
A phase 3 clinical trial evaluated damoctocog alfa pegol in previously treated children aged 7 to 12 years with severe haemophilia A.
A new treatment for severe haemophilia A in children aged 7 to 12 is being tested in a Phase 3 trial to check its safety and effectiveness.
Damoctocog alfa pegol shows safety and maintained bleed protection in children with severe haemophilia A
Study finds haemophilia drug safe and effective in children over six months
A phase 3, open-label, single-arm study of 35 previously treated children aged 7 to <12 years with severe haemophilia A found no adverse eve…
A haemophilia drug prevented bleeds in children aged 7 to under 12, with no severe side effects and no one stopping treatment due to bad rea…
Concizumab Reduces Bleeding in Hemophilia with Inhibitors: Median ABR 0.8 at 56 Weeks
Could a New Treatment Change the Lives of People with Hemophilia?
In the phase 3 explorer7 RCT, concizumab prophylaxis significantly reduced median annualized bleeding rate (ABR) to 0.8 in patients with hem…
A new treatment for hemophilia helped patients with inhibitors experience just one bleeding episode a year, offering hope for fewer interrup…